One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Nuvation Bio  logo
Nuvation Bio NUVB
$ 4.5 -1.42%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Nuvation Bio Financial Statements 2025-2011 | NUVB

Annual Financial Statements Nuvation Bio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.99 B 505 M 414 M 360 M 1.21 M - - - - - - - - - -

Shares

342 M 269 M 219 M 217 M 198 K - - - - - - - - - -

Historical Prices

5.83 1.88 1.89 1.66 6.1 10.2 - - - - - - - - -

Net Income

-205 M -568 M -75.8 M -104 M -86.8 M - - - - - - - - - -

Revenue

62.9 M 7.87 M - - - - - - - - - - - - -

Cost of Revenue

- 7.08 M - - - - - - - - - - - - -

Gross Profit

- 795 K - - - - - - - - - - - - -

Operating Income

-213 M -593 M -99.8 M -120 M -93.3 M -43.6 M - - - - - - - - -

Interest Expense

10.1 M -109 K - - - - - - - - - - - - -

EBITDA

-211 M -592 M -99.6 M -120 M -93.1 M - - - - - - - - - -

Operating Expenses

276 M 600 M 99.8 M 120 M 93.3 M - - - - - - - - - -

General and Administrative Expenses

152 M 69.2 M 28.5 M 31.9 M 24.3 M - - - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Nuvation Bio

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

349 M 347 M 342 K 341 K 339 K 338 M 274 K 245 K 219 K 219 M 219 K 219 K 219 K 219 M 218 K 217 K 213 K 218 M 207 K 204 K 170 K 149 M 91.8 K 88.7 K 85.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-62.8 M 5.4 M -55.8 M -59 M -53.2 M - -41.2 M -462 M -14.8 M - -19.6 M -20.6 M -21.7 M - -27.2 M -34.9 M -21.3 M - -22 M -19.3 M -20.4 M - -11 M -8.6 M -8.75 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

31.7 M 83.2 M 13.1 M 4.83 M 3.08 M - 727 K 1.44 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - 3.35 M 2.58 M 2.09 M - 1.52 M 1.35 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - 9.77 M 2.26 M 990 K - -788 K 88 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-51 M 3.88 M -56.4 M -63.6 M -59 M - -48.1 M -470 M -20.2 M - -26.3 M -26.1 M -26.5 M - -29.3 M -37.9 M -28.2 M - -22.8 M -20.4 M -20.5 M - -11.5 M -9.02 M -9.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - 5.12 M 266 K - - - 132 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-50 M 4.42 M - - -58.7 M - - - -20.1 M - - - -26.5 M - -29.2 M -37.9 M -28.1 M - -22.6 M -20.4 M -20.5 M - -11.5 M -8.97 M -9.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

82.7 M 79.3 M 66.2 M 65.8 M 60 M - 47.3 M 470 M 20.2 M - 26.3 M 26.1 M 26.5 M - 29.3 M 37.9 M 28.2 M - 22.8 M 20.4 M 20.5 M - 11.5 M 9.02 M 9.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

42.6 M 38.3 M 37.4 M 38.5 M 35.4 M - 19.6 M 16.2 M 7.36 M - 7.78 M 7.54 M 7.73 M - 8.04 M 8.95 M 7.46 M - 5.67 M 6.4 M 4.6 M - 2.92 M 1.67 M 1.92 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Nuvation Bio NUVB
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Nuvation Bio plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Ovid Therapeutics Ovid Therapeutics
OVID
$ 2.15 -0.23 % $ 280 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
- - $ 527 M usaUSA
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
- - $ 1.62 B israelIsrael
Puma Biotechnology Puma Biotechnology
PBYI
$ 10.85 -1.54 % $ 543 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 1.76 -2.76 % $ 2.3 M usaUSA
Vaxcyte Vaxcyte
PCVX
$ 59.95 -0.79 % $ 8.16 B usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
- - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Pfizer Pfizer
PFE
$ 29.8 -0.78 % $ 169 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
- - $ 26.6 B irlandaIrlanda
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 11.85 5.8 % $ 8.16 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 5.94 3.48 % $ 433 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
$ 0.87 2.04 % $ 5.21 M usaUSA
Lantern Pharma Lantern Pharma
LTRN
$ 0.6 -5.34 % $ 6.54 M usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
- - $ 121 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 0.85 -1.64 % $ 52.2 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
- -33.41 % $ 3.37 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
$ 267.68 5.82 % $ 6.02 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 0.74 0.07 % $ 480 K israelIsrael
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.69 1.65 % $ 284 M usaUSA
iTeos Therapeutics iTeos Therapeutics
ITOS
- - $ 411 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
$ 1.23 -4.65 % $ 130 M niderlandNiderland
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 8.38 2.2 % $ 451 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
$ 61.04 0.74 % $ 4.85 B usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
$ 140.24 1.31 % $ 8.92 B usaUSA
Pulmatrix Pulmatrix
PULM
$ 1.44 -2.7 % $ 5.26 B usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
- -47.76 % $ 6.27 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
$ 2.45 -5.91 % $ 21.1 M usaUSA
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
$ 16.09 2.78 % $ 1.59 B usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
$ 17.7 -4.53 % $ 1.9 B usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.43 0.57 % $ 5.3 B israelIsrael
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 808.08 0.38 % $ 84.5 B usaUSA
Replimune Group Replimune Group
REPL
$ 12.48 8.9 % $ 1.16 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Rafael Holdings Rafael Holdings
RFL
$ 1.18 -9.92 % $ 34.7 M usaUSA
REGENXBIO REGENXBIO
RGNX
$ 6.58 -1.5 % $ 339 M usaUSA
Kiromic BioPharma Kiromic BioPharma
KRBP
- 6.61 % $ 3.08 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 49.95 3.78 % $ 898 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.89 -2.84 % $ 177 M israelIsrael
Relay Therapeutics Relay Therapeutics
RLAY
$ 18.16 -0.11 % $ 3.12 B usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.0 -0.5 % $ 117 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
$ 64.76 1.4 % $ 27.8 B usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 89.56 0.32 % $ 5.82 B usaUSA
Rezolute Rezolute
RZLT
$ 3.82 -1.04 % $ 397 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA